Global Lymphangioleiomyomatosis Treatment Market, By Type (Tuberous Sclerosis Complex (TSC) –Lymphangioleiomyomatosis and Sporadic Lymphangioleiomyomatosis), Therapy Type (Oxygen Therapy and Antibiotic Therapy), Treatment (Medication and Surgery), Drugs (mTOR inhibitors, Sirolimus and Bronchodilators), Route of Administration (Intravenous and Oral), By End Users (Hospitals, Homecare, Specialty Clinics and Others), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Others), Country (U.S., Canada, Mexico, Peru, Brazil, Argentina, Rest of South America, Germany, Italy, U.K., France, Spain, Netherlands, Belgium, Switzerland, Turkey, Russia, Hungary, Lithuania, Austria, Ireland, Norway, Poland, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Vietnam, Rest of Asia Pacific, South Africa, Saudi Arabia, U.A.E, Kuwait, Israel, Egypt, Rest of Middle East and Africa) Industry Trends and Forecast to 2028.